SpineGuard Looks to Break Even by 2018, Names Co-Founder CEO Post author:Sam Post published:July 6, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like FDA Orders 6 Partial or Full Clinical Holds on Celgene's Blood Cancer Studies September 6, 2017 <b>Hearst</b> Invests In H. Lee Moffitt Cancer Center & Research Institute Subsidiary M2Gen September 19, 2017 FDA Approval of Drug May Have Made This Bay Area Pharma a New M&A Target June 26, 2017
<b>Hearst</b> Invests In H. Lee Moffitt Cancer Center & Research Institute Subsidiary M2Gen September 19, 2017